Shares of Marksans Pharma Ltd were trading in the green and 2% higher on 28 May after the company announced securing approval from the UK health regulators to market new oral solutions. 

In its regulatory filing, the company said that its wholly-owned subsidiary Reonchem has received the marketing authorisation from UK MHRA for Levetiracetam Relonchem 100 mg/mL Oral Solution. 

The Levetiracetam will be manufactured at the company’s UK manufacturing facility and is used to treat epilepsy and help control certain types of seizures. 

Earlier on 15 April, the Massachusetts Institute of Technology (MIT) acquired 66 lakh shares, which represent a 1.45% stake in the company. Apart from MIT, nine other fund houses have acquired a total of 4.23% equity in the company. 

According to the company, OrbiMed Asia IV Mauritius FVCI holds a 10.88% stake, while Quant Smallcap Fund holds a 2.79% stake.

The company primarily focuses on over-the-counter segments and soft gel products in the US and UK markets. The product portfolio is heavily weighted towards these areas. One advantage of over-the-counter drugs is that this segment tends to be more stable compared to traditional generics, which often experience issues with declining prices.

At 3:30 pm, the shares of Marksans Pharma closed 0.64% higher at Rs 165.80 on NSE.